| Xianglin Yuan. Progress in the research of digestive system oncology. Oncol Transl Med, 2015, 1: 97-98. |
| Progress in research on digestive system oncology |
| Progress in the research of digestive system oncology |
| Received:May 11, 2015 Revised:May 11, 2015 |
| DOI：10.1007/s10330-015-0095-7 |
| 中文关键词: digestive system oncology |
| 英文关键词: digestive system oncology |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xianglin Yuan* | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei province, China | xlyuan1020@163.com |
|
| Hits: 8240 |
| Download times: 9903 |
| 中文摘要: |
| Xianglin Yuan, Professor of Oncology, Doctoral Supervisor, Deputy Director of the Oncology Department and Director of the Digestive System Oncology Department, Tongji Hospital,
Tongji Medical College of HUST, China. Yuan discovered that CT/CC genotypes of the TGFbeta1 rs1982073: T869C gene were associated with a low risk of radiation pneumonitis (RP) in patientswith non-small cell lung cancer (NSCLC) treated with definitive radio(chemo)therapy and thus might serve as a reliable predictor of RP (Journal of Clinical Oncology, 2009; cited over 70 times). He indicated that genetic variations in PI3K-AKT-mTOR could predict brain metastasis in patients with NSCLC (Journal of Clinical Cancer Research, 2014). He also discovered that among the candidate genes involved in the TGF-β pathway, polymorphisms of SMAD3 appeared to be highly predictive of outcome in patients with lung adenocarcinoma after gefitinib treatment, especially in those with epidermal growth factor receptor mutations (Annals of Oncology, 2014). He has published about 30 articles found in the Science Citation Index (SCI) and has managed 3 items of the National Natural Science Foundation of China. He is an expert in radiation therapy and comprehensive therapy for common malignant tumors such as esophageal, gastric, liver, colorectal, and lung cancers. He now holds the following responsible positions: Chairman, Oncology Committee, Wuhan Medical Association; Chairman, Committee of Molecular Marker and Translational Medicine, Hubei Anti-Cancer Association; Vice Chairman, Committee of Radiation Therapy, Hubei Anti-Cancer Association; Member, Executive Committee, Chinese Society of Clinical Oncology; member, Committee of Tumor Marker, Chinese Anti-Cancer Association. |
| 英文摘要: |
| Xianglin Yuan, Professor of Oncology, Doctoral Supervisor, Deputy Director of the Oncology Department and Director of the Digestive System Oncology Department, Tongji Hospital,
Tongji Medical College of HUST, China. Yuan discovered that CT/CC genotypes of the TGFbeta1 rs1982073: T869C gene were associated with a low risk of radiation pneumonitis (RP) in patientswith non-small cell lung cancer (NSCLC) treated with definitive radio(chemo)therapy and thus might serve as a reliable predictor of RP (Journal of Clinical Oncology, 2009; cited over 70 times). He indicated that genetic variations in PI3K-AKT-mTOR could predict brain metastasis in patients with NSCLC (Journal of Clinical Cancer Research, 2014). He also discovered that among the candidate genes involved in the TGF-β pathway, polymorphisms of SMAD3 appeared to be highly predictive of outcome in patients with lung adenocarcinoma after gefitinib treatment, especially in those with epidermal growth factor receptor mutations (Annals of Oncology, 2014). He has published about 30 articles found in the Science Citation Index (SCI) and has managed 3 items of the National Natural Science Foundation of China. He is an expert in radiation therapy and comprehensive therapy for common malignant tumors such as esophageal, gastric, liver, colorectal, and lung cancers. He now holds the following responsible positions: Chairman, Oncology Committee, Wuhan Medical Association; Chairman, Committee of Molecular Marker and Translational Medicine, Hubei Anti-Cancer Association; Vice Chairman, Committee of Radiation Therapy, Hubei Anti-Cancer Association; Member, Executive Committee, Chinese Society of Clinical Oncology; member, Committee of Tumor Marker, Chinese Anti-Cancer Association. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|